Sera Prognostics Q1 revenue falls sharply, net loss widens

Sera Prognostics

06/05/2026 21:39

Overview

Pregnancy diagnostics firm's Q1 revenue fell sharply yr/yr

Net loss for Q1 widened slightly from prior year

Company extended cash runway through 2029 after cost structure changes

Outlook

Company expects cash resources to fund operations through 2029

Company advancing toward CE marking in Europe with regulatory submission on track for mid-year

Company focusing on commercialization and expanding clinician engagement in targeted markets

Result Drivers

COMMERCIAL INVESTMENT - Co said higher selling, general and administrative expenses reflected targeted commercial activities and strategic headcount additions after PRIME study publication

SHIFT TO COMMERCIALIZATION - Co said it redirected investment from clinical spend toward reimbursement-driven commercialization, aiming for a sustainable cost structure

Company press release: ID:nPn2BLzLna

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$14,000
$80,000 (2 Analysts)
Q1 EPS
-$0.17


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the business support services peer group is "buy"

Wall Street's median 12-month price target for Sera Prognostics Inc is $5.00, about 166% above its May 5 closing price of $1.88

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)